Ó£»¨ÊÓƵ

Effectiveness against morbidity, Cholera Infection: Low-outcome-specific quality

02 [6, 32]

RCT/Quasi

One study was a Quasi Experimental Design

All studies show consistent benefit

Results can be generalised to population in developing countries

Included WC and BS-WC oral vaccines

63

75

0.48 [0.35, 0.64]^a

O1 [5]

Case Control

Random model used

Study was conducted in Mozambique

BS-WC vaccine

2

22

0.18 (0.03, 1.08)

Efficacy against morbidity, Cholera Infection: High-outcome-specific quality

02 [29, 33]

RCT

All studies show consistent benefit

Results can be generalised to population in developing countries

Included WC and CVD 103-HgR live oral Vaccines

11

13

0.90 [0.40, 2.03]^a

Efficacy/Effectiveness against morbidity- Cholera Infection (Various Types of vaccines)

03 [6, 32, 33]

RCT/Quasi

One study was a quasi-experimental design

Two studies showed significant impact

Results can be generalised to population in developing countries

WC Vaccines

45

85

0.53 [0.36, 0.76]^b

01 [32]

RCT

Only one study

Study was conducted in Bangladesh

BS-WC Vaccines

26

56

0.47 [0.30, 0.74]

01 [29]

RCT

Only one study

Study was conducted in Indonesia

CVD 103-HgR live oral

03

03

1.00 [0.20, 5.00]

Vibriocidal antibody: Low outcome-specific quality

07 [23, 25, 27–30, 65]

RCT

None

Results from analysis significant. Five studies show benefit

All from Developing Countries

All Oral Vaccines

503

234

2.24 (1.32, 3.80)^b

03 [23, 27, 31]

RCT

Two studies show benefit

All from Developing Countries

Oral Killed Vaccines

202

205

0.97 [0.75, 1.25]^b

04 [25, 28–30]

RCT

Three studies show significant benefit

All from Developing Countries

Oral Live Vaccines

301

29

10.73 [1.94, 59.37]^b

One or more Adverse effect: Low outcome-specific quality

06 [24, 25, 27, 28, 30, 32, 33]

RCT

None

significant results

All from developing countries

All Oral Vaccines

132

91

1.42 (1.06, 1.89)^a